Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease

被引:55
作者
Ode, Hirotaka
Matsuyama, Shou
Hata, Masayuki
Neya, Saburo
Kakizawa, Junko
Sugiura, Wataru
Hoshino, Tyuji
机构
[1] Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan
[2] Natl Inst Infectious Dis, AIDS Res Ctr, Tokyo 2081011, Japan
[3] JST, PRESTO, Kawaguchi, Saitama 3320012, Japan
基金
日本科学技术振兴机构; 日本学术振兴会;
关键词
HIV-1; protease; resistance; M361; non-active site mutation; ORALLY BIOAVAILABLE INHIBITOR; FREE-ENERGY CALCULATIONS; DRUG-RESISTANCE; HIV-1; PROTEASE; MOLECULAR-DYNAMICS; SUBTYPE-C; REVERSE-TRANSCRIPTASE; CONTINUUM SOLVENT; POTENT; MECHANISM;
D O I
10.1016/j.jmb.2007.04.081
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A prominent characteristic of human immunodeficiency virus type 1 (HIV-1) is its high genetic variability, which generates diversity of the virus and often causes a serious problem of the emergence of drug-resistant mutants. Subtype B HIV-1 is dominant in advanced countries, and the mortality rate due to subtype B HIV-1 has been decreased during the past decade. In contrast, the number of patients with non-subtype B viruses is still increasing in developing countries. One of the reasons for the prevalence of non-subtype B viruses is lack of information about the biological and therapeutic differences between subtype B and non-subtype B viruses. M361 is the most frequently observed polymorphism in non-subtype B HIV-1 proteases. However, since the 36th residue is located at a non-active site of the protease and has no direct interaction with any ligands, the structural role of M361 remains unclear. Here, we performed molecular dynamics (MD) simulations of M361 protease in complex with nelfinavir and revealed the influence of the M361 mutation. The results show that M361 regulates the size of the binding cavity of the protease. The reason for the rare emergence of D30N variants in non-subtype B HIV-1 proteases was also clarified from our computational analysis. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:598 / 607
页数:10
相关论文
共 54 条
[1]   Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G [J].
Abecasis, AB ;
Deforche, K ;
Snoeck, J ;
Bacheler, LT ;
McKenna, P ;
Carvalho, AP ;
Gomes, P ;
Camacho, RJ ;
Vandamme, AM .
AIDS, 2005, 19 (16) :1799-1806
[2]  
[Anonymous], 2006, JOINT UN PROGR HIV A
[3]   Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (Subtype E) infection differ from subtype B infection [J].
Ariyoshi, K ;
Matsuda, M ;
Miura, H ;
Tateishi, S ;
Yamada, T ;
Sugiura, W .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (03) :336-342
[4]   Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia [J].
Batista, PR ;
Wilter, A ;
Durham, EHAB ;
Pascutti, PG .
CELL BIOCHEMISTRY AND BIOPHYSICS, 2006, 44 (03) :395-404
[5]   Does the world need another AIDS authority? [J].
Billingham, Dan .
LANCET, 2006, 368 (9548) :1639-1640
[6]   Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom [J].
Cane, PA ;
de Ruiter, A ;
Rice, P ;
Wiselka, M ;
Fox, R ;
Pillay, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) :2652-2654
[7]   In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor [J].
Carrillo, A ;
Stewart, KD ;
Sham, HL ;
Norbeck, DW ;
Kohlbrenner, WE ;
Leonard, JM ;
Kempf, DJ ;
Molla, A .
JOURNAL OF VIROLOGY, 1998, 72 (09) :7532-7541
[8]  
Case D.A., 2004, AMBER, V8
[9]   Analysis of HIV-1CRF_01 A/E protease inhibitor resistance: Structural determinants for maintaining sensitivity and developing resistance to atazanavir [J].
Clemente, JC ;
Coman, RM ;
Thiaville, MM ;
Janka, LK ;
Jeung, JA ;
Nukoolkarn, S ;
Govindasamy, L ;
Agbandje-McKenna, M ;
McKenna, R ;
Leelamanit, W ;
Goodenow, MM ;
Dunn, BM .
BIOCHEMISTRY, 2006, 45 (17) :5468-5477
[10]   Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N [J].
Clemente, JC ;
Hemrajani, R ;
Blum, LE ;
Goodenow, MA ;
Dunn, BA .
BIOCHEMISTRY, 2003, 42 (51) :15029-15035